These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 35351965)
1. Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. Yang FC; Wang C; Zhu J; Gai QJ; Mao M; He J; Qin Y; Yao XX; Wang YX; Lu HM; Cao MF; He MM; Wen XM; Leng P; Cai XW; Yao XH; Bian XW; Wang Y Lab Invest; 2022 Jul; 102(7):741-752. PubMed ID: 35351965 [TBL] [Abstract][Full Text] [Related]
2. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. de Souza I; Monteiro LKS; Guedes CB; Silva MM; Andrade-Tomaz M; Contieri B; Latancia MT; Mendes D; Porchia BFMM; Lazarini M; Gomes LR; Rocha CRR Cell Death Dis; 2022 Jul; 13(7):591. PubMed ID: 35803910 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma. Liu J; Gao L; Zhan N; Xu P; Yang J; Yuan F; Xu Y; Cai Q; Geng R; Chen Q J Exp Clin Cancer Res; 2020 Jul; 39(1):137. PubMed ID: 32677981 [TBL] [Abstract][Full Text] [Related]
4. The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. Shi L; Chen H; Chen K; Zhong C; Song C; Huang Y; Wang T; Chen L; Li C; Huang A; Qi S; Li H; Lu Y Clin Cancer Res; 2023 Aug; 29(16):3172-3188. PubMed ID: 37249604 [TBL] [Abstract][Full Text] [Related]
5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
6. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553 [TBL] [Abstract][Full Text] [Related]
7. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis. Wei Y; Duan S; Gong F; Li Q Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905 [TBL] [Abstract][Full Text] [Related]
9. LINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis. Luo C; Nie C; Zeng Y; Qian K; Li X; Wang X Mol Neurobiol; 2022 Jun; 59(6):3829-3844. PubMed ID: 35420382 [TBL] [Abstract][Full Text] [Related]
10. A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma. Miao Z; Xu L; Gu W; Ren Y; Li R; Zhang S; Chen C; Wang H; Ji J; Chen J Redox Biol; 2024 Jul; 73():103220. PubMed ID: 38838551 [TBL] [Abstract][Full Text] [Related]
11. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
12. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
13. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. Babu D; Mudiraj A; Yadav N; Y B V K C; Panigrahi M; Prakash Babu P Cell Oncol (Dordr); 2021 Aug; 44(4):889-905. PubMed ID: 33948872 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105 [TBL] [Abstract][Full Text] [Related]
16. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. Fabro F; Kers TV; Feller KJ; Beerens C; Ntafoulis I; Idbaih A; Verreault M; Connor K; Biswas A; Salvucci M; Prehn JHM; Byrne AT; O'Farrell AC; Lambrechts D; Dilcan G; Lodi F; Arijs I; Kremer A; Tching Chi Yen R; Chien MP; Lamfers MLM; Leenstra S Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958662 [TBL] [Abstract][Full Text] [Related]
17. Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide. Wang H; Wu B; Wang J; Hu Y; Dai X; Ye L; Cheng H Clin Neurol Neurosurg; 2021 Jan; 200():106344. PubMed ID: 33153768 [TBL] [Abstract][Full Text] [Related]
18. Role of COL6A2 in malignant progression and temozolomide resistance of glioma. Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182 [TBL] [Abstract][Full Text] [Related]
20. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]